CD274 and neoplasm: Currently, different IHC assays have different PD-L1 expression cutoffs and scoring is either only on tumor cells (nivolumab, durvalumab, avelumab), only on tumor-infiltrating ICs (atezolizumab), or on the combination of tumor cells and ICs (pembrolizumab).